

<http://www.oblible.com>

424B2 1 d424b2.htm PRICING SUPPLEMENT 14Y BARC STEP-UP WITH SURVIVOR OPTION BLACK  
CALCULATION OF REGISTRATION FEE

<i>Title of Each Class of Securities Offered</i>	<i>Maximum Aggregate Offering Price</i>	<i>A</i>
Global Medium-Term Notes, Series A	\$369,000	

(1) Calculated in accordance with Rule 457(r) of the Securities Act of 1933.

**<http://www.oblible.com>**

---

Pricing Supplement dated September 13, 2010  
(To Prospectus dated August 31, 2010 and  
the Prospectus Supplement dated August 31, 2010)

<http://www.sec.gov/Archives/edgar/data/312070/000119312510210627/d424b2.htm>

## Pricing Supplement 14Y BARC Step-up with Survivor Option Black



US\$369,000

### STEP UP FIXED RATE NOTES DUE SEPTEMBER 16, 2024

<b>Principal Amount:</b>	US\$369,000	<b>Issuer:</b>	Barclays Bank PLC
<b>Issue Price:</b>	100%	<b>Series:</b>	Global Medium-Term N
<b>Original Issue Date:</b>	September 16, 2010	<b>Principal Protection Percentage:</b>	If you hold the Notes to maturity, you will receive at least 100% of the principal, subject to the creditworthiness of Barclays Bank PLC. The Notes are not insured or indirectly, an obligation of any party, and any payment on the Notes, including any principal protection provided at maturity, depends on the ability of Barclays Bank PLC to satisfy its obligations when they come due.
<b>Interest Rate Type:</b>	Fixed Rate	<b>Original Trade Date:</b>	September 13, 2010
<b>Maturity Date:</b>	September 16, 2024	<b>CUSIP:</b>	06738JBR4
		<b>ISIN:</b>	US06738JBR41
<b>Denominations:</b>	Minimum denominations of US\$1,000 and integral multiples of US\$1,000 thereafter.	<b>Business Day:</b>	<input checked="" type="checkbox"/> New York <input checked="" type="checkbox"/> London <input type="checkbox"/> Euro <input type="checkbox"/> Other ( )
<b>Interest Rate:</b>	<ul style="list-style-type: none"> <li>For each Interest Period commencing on or after the Original Issue Date, to but excluding September 16, 2020, the interest rate per annum will be equal to: 4.00% per annum</li> <li>For each Interest Period commencing on September 16, 2020, to but excluding September 16, 2023, the interest rate per annum will be equal to: 4.50% per annum</li> <li>For each Interest Period commencing on September 16, 2023, to but excluding the Maturity Date, the interest rate per annum will be equal to: 6.00% per annum</li> </ul>		
<b>Interest Payment Dates:</b>	<input type="checkbox"/> Monthly, <input type="checkbox"/> Quarterly, <input checked="" type="checkbox"/> Semi-Annually, <input type="checkbox"/> Annually payable in arrears on every 16 <sup>th</sup> of March and September, commencing on March 16, 2011 and ending on the Maturity Date.		
<b>Interest Period:</b>	The initial Interest Period will begin on, and include, the Original Issue Date and end on, but exclude, the first Interest Payment Date. Each subsequent Interest Period will begin on, and include, the Interest Payment Date of the preceding Interest Period and end on, but exclude, the next following Interest Payment Date. The final Interest Period will end on, but exclude, the Maturity Date.		
<b>Survivor's Option:</b>	Upon request by the authorized representative of the beneficial owner of the Notes, we will repay the principal of the Notes prior to the Maturity Date following the death of the beneficial owner of the Notes, provided such request is received and acquired by the deceased beneficial owner at least six months prior to the date of the request. The right to exercise this option will be subject to: <ul style="list-style-type: none"> <li>a permitted dollar amount of total exercises by all holders of these Notes in any calendar</li> </ul>		

Pricing Supplement 14Y BARC Step-up with Survivor Option Black

Pricing Supplement 14Y BARC Step-up with Survivor Option Black

---

## Pricing Supplement 14Y BARC Step-up with Survivor Option Black

	Price to Public	Agent's Commission <sup>(1)</sup>	Proceeds to Barclays Bank P
Per Note	100%	1.65%	98.35%
Total	\$369,000	\$6,088.50	\$362,911.50

(1) Barclays Capital Inc. will receive commissions from the Issuer equal to 1.65% of the principal amount of the notes, or \$16.50 per \$1,000 principal amount, and may use all or a portion of these commissions or use all or a portion of these commissions to pay selling concessions or fees to other dealers.

The Notes will not be listed on any U.S. securities exchange or quotation system. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined that this pricing supplement is truthful or complete. Any representation to the contrary is a criminal offense.

We may use this pricing supplement in the initial sale of Notes. In addition, Barclays Capital Inc. or another of our affiliates may use this pricing supplement in market resale transactions in any Notes after their initial sale. Unless we or our agent informs you otherwise in the confirmation of sale, this pricing supplement is being used in a market resale transaction.



Pricing Supplement 14Y BARC Step-up with Survivor Option Black

## Pricing Supplement 14Y BARC Step-up with Survivor Option Black

---

The Notes constitute our direct, unconditional, unsecured and unsubordinated obligations and are not deposit liabilities of Barclays Bank PLC or any other governmental agency of the United States, the United Kingdom or any other country.

Investing in the Notes involves a number of risks. See “Risk Factors” beginning on page S-5 of the prospectus supplement and “Selected Risk Factors” beginning on page S-6 of the prospectus supplement. You should consult your investment, legal, tax, accounting and other advisers and to invest in the Notes only after you and your advisers have considered the suitability of an investment in the Notes in light of your particular circumstances.

Barclays Bank PLC has filed a registration statement (including a prospectus) with the SEC for the offering to which this pricing supplement relates. You should read the prospectus dated August 31, 2010, the prospectus supplement dated August 31, 2010, and other documents Barclays Bank PLC has filed with the SEC for more complete information about Barclays Bank PLC and this offering. Buyers should rely upon this pricing supplement, the prospectus, the prospectus supplement, and any relevant free writing prospectus for complete details. You may get these documents and other documents Barclays Bank PLC has filed with the SEC by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov), and you may also access the prospectus and prospectus supplement through the following links:

- **Prospectus dated August 31, 2010:**  
<http://www.sec.gov/Archives/edgar/data/312070/000119312510201448/df3asr.htm>
- **Prospectus Supplement dated August 31, 2010:**  
<http://www.sec.gov/Archives/edgar/data/312070/000119312510201604/d424b3.htm>

Our Central Index Key, or CIK, on the SEC website is 1-10257.

Alternatively, Barclays Capital Inc. or any agent or dealer participating in this offering will arrange to send you this pricing supplement and any relevant free writing prospectus if you request it by calling your Barclays Capital Inc. sales representative, such as (Extension 2-3430). A copy of the prospectus may be obtained from Barclays Capital Inc., 745 Seventh Avenue—Attn: US InvSol Sales.

You may revoke your offer to purchase the Notes at any time prior to the time at which we accept such offer by notifying the applicable agent or dealer of, or reject any offer to purchase the Notes prior to their issuance. In the event of any changes to the terms of the Notes, we will notify you of such changes in connection with your purchase. You may also choose to reject such changes in which case we may reject your offer to purchase the Notes.

As used in this term sheet, the “Company,” “we,” “us,” or “our” refers to Barclays Bank PLC.



---

## SELECTED RISK FACTORS

An investment in the Notes involves significant risks. You should read the risks summarized below in connection with, and the risks described in more detail in the “Risk Factors” section beginning on page S-5 of the prospectus supplement. You should consult your investment, legal, tax, accounting and other advisers and to invest in the Notes only after you and your advisers have carefully considered the risks in the Notes in light of your particular circumstances.

- **Issuer Credit Risk**—The Notes are our unsecured debt obligations, and are not, either directly or indirectly, an obligation of Barclays Bank PLC. The ability to make on the Notes, including any principal protection provided at maturity, depends on our ability to satisfy our obligations and the creditworthiness of Barclays Bank PLC may affect the market value of the Notes and, in the event we were to default, we may not receive the principal protection or any other amounts owed to you under the terms of the Notes.
- **Certain Built-In Costs Are Likely to Adversely Affect the Value of the Notes Prior to Maturity**—Although you will not receive interest on the Notes if you hold the Notes to maturity, the Original Issue Price of the Notes includes the agent’s commission and the cost of the Notes through one or more of our affiliates. As a result, assuming no change in market conditions or any other relevant factors, Barclays Bank PLC and other affiliates of Barclays Bank PLC will be willing to purchase Notes from you in secondary market transactions at the Original Issue Price, and any sale prior to the Maturity Date could result in a substantial loss to you.
- **Potential Conflicts**—We and our affiliates play a variety of roles in connection with the issuance of the Notes, including hedging and performing these duties, the economic interests of our affiliates of ours are potentially adverse to your interests as an investor. In addition, Barclays Wealth, the wealth management division of Barclays Capital Inc., may arrange for the sale of the Notes through Barclays Bank PLC. Barclays Wealth will be acting as agent for Barclays Bank PLC and may receive compensation from Barclays Bank PLC in the event of the sale of the Notes. The role of Barclays Wealth as a provider of certain services to such customers and as agent for Barclays Bank PLC in connection with the sale of the Notes to investors may create a potential conflict of interest, which may be adverse to such clients. Barclays Wealth is not acting as an investment adviser to investors and is not representing you in any capacity with respect to any purchase of Notes by you. Barclays Wealth is acting solely as agent for Barclays Bank PLC. When considering whether to invest in the Notes through Barclays Wealth, we strongly urge you to seek independent financial and legal advice in connection with such investment.
- **Lack of Liquidity**—The Notes will not be listed on any securities exchange. Barclays Capital Inc. and other affiliates of Barclays Bank PLC may create a secondary market for the Notes but are not required to do so, and may discontinue any such secondary market making at any time. If there is no active secondary market, it may not provide enough liquidity to allow you to trade or sell the Notes easily. Because other dealers are not making a market for the Notes, the price at which you may be able to trade your Notes is likely to depend on the price, if any, at which Barclays Bank PLC are willing to buy the Notes. The Notes are not designed to be short-term trading instruments. Accordingly, you may not be able to hold your Notes to maturity.
- **Many Economic and Market Factors Will Impact the Value of the Notes**—The value of the Notes will be affected by a number of factors, some of which may either offset or magnify each other, including:
  - the time to maturity of the Notes;
  - interest and yield rates in the market generally;
  - a variety of economic, financial, political, regulatory or judicial events; and
  - our creditworthiness, including actual or anticipated downgrades in our credit ratings.

## Pricing Supplement 14Y BARC Step-up with Survivor Option Black

---

### DESCRIPTION OF SURVIVOR'S OPTION

Upon request by the authorized representative of the beneficial owner of the Notes, Barclays Bank PLC will repay those Notes prior to the Maturity Date of the Notes (the “**Survivor’s Option**”), provided such Notes were acquired by the deceased beneficial owner at least six months prior to the death of the deceased beneficial owner. Upon the valid exercise of the Survivor’s Option and the proper tender of the Notes for repayment, Barclays Bank PLC will repay such Notes to 100% of the principal amount of the deceased beneficial owner’s beneficial interest in the Notes plus accrued and unpaid interest to the date of death. For purposes of this section, a beneficial owner of Notes is a person who has the right, immediately prior to such person’s death, to receive the proceeds from the sale of the Notes or the right to receive payment of the principal of the Notes.

To be valid, the Survivor’s Option must be exercised by or on behalf of the person who has authority to act on behalf of the deceased beneficial owner of the applicable jurisdiction (including, without limitation, the personal representative of or the executor of the estate of the deceased beneficial owner or a person acting in concert with the deceased beneficial owner).

The death of a person holding a beneficial ownership interest in the Notes: (1) with any person in a joint tenancy with right of survivorship; (2) by the entirety, tenancy in common, as community property or in any other joint ownership arrangement, will be deemed the death of a beneficial owner. The entire principal amount of the Notes held in this manner will be subject to repayment by Barclays Bank PLC upon request. However, the death of a person holding a beneficial ownership interest in Notes as tenant in common with a person other than his or her spouse will be deemed the death of a beneficial owner of the person’s interest in the Notes, and only the deceased beneficial owner’s percentage interest in the principal amount of the Notes will be subject to repayment.

If the ownership interest in the Notes is held by a nominee for a beneficial owner or by a custodian under a Uniform Gifts to Minors Act or a trustee of a trust that is wholly revocable by the beneficial owner, or by a guardian or committee for a beneficial owner, the death of the beneficial owner will constitute death of the beneficial owner for purposes of the Survivor’s Option, if the beneficial ownership interest can be established to the satisfaction of Barclays Bank PLC. In these cases, the death of the nominee, custodian, trustee, guardian or committee will not be deemed the death of the beneficial owner of the Notes for purposes of the Survivor’s Option.

Barclays Bank PLC has the discretionary right to limit the aggregate principal amount of the Notes as to which exercises of the Survivor’s Option may be made by authorized representatives of deceased beneficial owners in any calendar year, to an amount equal to 2.0% of the aggregate amount of the Notes outstanding as of the most recent calendar year.

Barclays Bank PLC also has the discretionary right to limit to \$250,000 the aggregate principal amount of Notes as to which exercises of the Survivor’s Option may be made by authorized representatives of deceased beneficial owners of such notes in any calendar year. In addition, Barclays Bank PLC may permit the exercise of the Survivor’s Option (a) for a principal amount less than \$1,000, or (b) if such exercise will result in a beneficial owner having a principal amount of less than \$1,000 outstanding.

An otherwise valid election to exercise the Survivor’s Option may not be withdrawn. Elections to exercise the Survivor’s Option will be accepted by Barclays Bank PLC, except for any election the acceptance of which would contravene any of the limitations described above. Notes tendered through the exercise of the Survivor’s Option will be repaid on the first Interest Payment Date that occurs 60 or more calendar days after the date of the election to Barclays Bank PLC. Each tendered Note that is not accepted in any calendar year due to the application of any of the limitations described above will be deemed to be tendered in the following calendar year in the order in which all such Notes were originally tendered. If a Note tendered through the exercise of the Survivor’s Option is not accepted by Barclays Bank PLC, the trustee, upon receipt of a valid written instruction from Barclays Bank PLC or its agent, will deliver the Note to the holder that states the reason that Note has not been accepted for repayment.

Because the Notes will be issued in book-entry form (except in very limited circumstances), DTC or its nominee will be treated as the holder of record of the Notes that receives notices from Barclays Bank PLC (or the trustee) and, on behalf of the deceased beneficial owner’s authorized representative, will exercise the Survivor’s Option for such Notes. To obtain repayment of the Notes pursuant to exercise of the Survivor’s Option, the deceased beneficial owner must

## Pricing Supplement 14Y BARC Step-up with Survivor Option Black

must provide the following items to the broker or other entity through which the beneficial interest in the Notes is held by the deceased beneficiary:

- appropriate evidence satisfactory to Barclays Bank PLC that:
  - (1) the deceased was the beneficial owner of the Notes at the time of death and his or her interest in the Notes was acquired at least six months prior to the request for repayment,
  - (2) the death of the beneficial owner has occurred and the date of death, and

PS-2

## Pricing Supplement 14Y BARC Step-up with Survivor Option Black

- 
- (3) the representative has authority to act on behalf of the deceased beneficial owner;
  - if the beneficial interest in the Notes is held by a nominee or trustee of, custodian for, or other person in a similar capacity to, evidence satisfactory to Barclays Bank PLC from the nominee, trustee, custodian or similar person attesting to the deceased's ownership of the beneficial interest in the Notes;
  - a written request for repayment signed by the authorized representative of the deceased beneficial owner with the signature guaranteed in the Security Transfer Agents Medallion Program, the New York Stock Exchange Medallion Signature Program or the Stock Exchange Medallion Signature Program (generally a member of a registered national securities exchange, a member of the Financial Industry Regulatory Authority, or having an office in the United States);
  - tax waivers and any other instruments or documents that Barclays Bank PLC reasonably requires in order to establish the validity of the Notes and the claimant's entitlement to payment; and
  - any additional information Barclays Bank PLC requires to evidence satisfaction of any conditions to the exercise of the Survivor Option or ownership or authority to make the election and to cause the repayment of the Notes.

In turn, the broker or other entity will deliver each of these items, through the appropriate direct participant in DTC and the facilities of DTC, in the form of notice (the "Form of Notice"), to the trustee and to Barclays Bank PLC and will certify to Barclays Bank PLC that the broker or other entity is the authorized representative of the deceased beneficial owner. The broker or other entity will be responsible for disbursing payments received from the trustee, through the facilities of DTC, to the beneficial owner.

During any time in which the Notes are not represented by a global note and are issued in definitive form:

- all references in this section to participants and DTC, including the DTC's governing rules, regulations and procedures, will be deemed to refer to the applicable provisions of the DTC's governing rules, regulations and procedures;
- all determinations that the DTC participants are required to make as described in this section will be made by Barclays Bank PLC, in determining whether the applicable decedent is in fact the beneficial owner of the interest in the Notes to be redeemed or is in fact duly authorized to request redemption on behalf of the applicable beneficial owner; and
- all redemption requests, to be effective, must:
  - be delivered by the representative to Barclays Bank PLC and to the trustee;
  - be made by completing the Form of Notice in accordance with the related instructions; and
  - be accompanied by, if applicable, a properly executed assignment or endorsement, in addition to all documents required to accompany a redemption request. If the record holder of the Note is a nominee of the deceased beneficial owner, a nominee attesting to the deceased's ownership of a beneficial interest in the Note must also be delivered.

Barclays Bank PLC retains the right to limit the aggregate principal amount of Notes as to which exercises of the Survivor's Option will be made by representatives of deceased beneficial owners and from the authorized representative for any individual deceased beneficial owner in any other questions regarding the eligibility or validity of any exercise of the Survivor's Option generally will be determined by Barclays Bank PLC and binding on all parties.

The Form of Notice may be obtained from Barclays Bank PLC, 745 Seventh Avenue, New York, NY 10019, Attention: US-Syndicate, MTN.

### UNITED STATES FEDERAL INCOME TAX TREATMENT

The following discussion supplements the discussion in the prospectus supplement under the heading "Certain U.S. Federal Income Tax Consequences" to the extent inconsistent therewith. The following discussion (in conjunction with the discussion in the prospectus supplement) summarizes certain tax consequences of the purchase, beneficial ownership, and disposition of the Notes.

## Pricing Supplement 14Y BARC Step-up with Survivor Option Black

We intend to treat the Notes as indebtedness for U.S. federal income tax purposes and any reports to the Internal Revenue Service (the “IRS”) with such treatment, and each holder will agree to treat the Notes as indebtedness for U.S. federal income tax purposes. The discussion that

PS-3

## Pricing Supplement 14Y BARC Step-up with Survivor Option Black

A U.S. holder will be taxable on interest income equal to the minimum coupon amount that will be paid on the Notes (the “Minimum Coupon Amount”) received in accordance with the U.S. Holder’s normal method of tax accounting. The Notes will be treated as having “original issue discount” for tax purposes in an amount equal to the excess of the aggregate interest payments on the Notes over the aggregate Minimum Coupon Amount of the Notes outstanding until their maturity. You will be required to include OID in income on a constant yield basis during your ownership of the Notes. If the income in respect of the Notes will exceed the cash interest payments you receive. See “U.S. Federal Income Tax Considerations—Original Issue Discount” in the pricing supplement.

### **3.8% Medicare Tax On “Net Investment Income”**

Beginning in 2013, U.S. holders that are individuals, estates, and certain trusts will be subject to an additional 3.8% tax on all or a portion of their net investment income. The net investment income may include the interest payments and any gain realized with respect to the Notes, to the extent of their net investment income that when added to their gross income, exceeds \$200,000 for an unmarried individual, \$250,000 for a married taxpayer filing a joint return (or a surviving spouse), or \$125,000 for a trust filing a separate return. U.S. holders should consult their advisors with respect to their consequences with respect to the 3.8% Medicare tax.

### **Information Reporting**

Holders that are individuals (and, to the extent provided in future regulations, entities) may be subject to certain foreign financial asset reporting requirements on the Notes if the aggregate value of their Notes and their other “specified foreign financial assets” exceeds \$50,000. Significant penalties can apply for failure to report specified foreign financial assets. This information reporting requirement is generally applicable for taxable years beginning after March 18, 2011. Consult your tax advisor with respect to this and other reporting obligations with respect to your Notes.

**PROSPECTIVE PURCHASERS SHOULD CONSULT THEIR TAX ADVISORS AS TO THE FEDERAL, STATE, LOCAL, AND OTHER TAX CONSEQUENCES OF THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF NOTES.**

### **CERTAIN EMPLOYEE RETIREMENT INCOME SECURITY ACT CONSIDERATIONS**

Your purchase of a Note in an Individual Retirement Account (an “IRA”), will be deemed to be a representation and warranty by you, as a fiduciary of the IRA, that (i) neither the issuer, the placement agent nor any of their respective affiliates has or exercises any discretionary authority over or with respect to the IRA assets used to purchase the Note or renders investment advice (within the meaning of Section 3(21)(A)(ii) of the Employee Retirement Income Security Act (“ERISA”)) with respect to any such IRA assets and (ii) in connection with the purchase of the Note, the IRA will pay no more than “adequate consideration” (within the meaning of Section 408(b)(17) of ERISA) and in connection with any redemption of the Note pursuant to its terms will receive at least adequate consideration. By making the foregoing representations and warranties, you have (x) applied sound business principles in determining whether fair market value will be paid for the Note and (y) acting in good faith.

For additional ERISA considerations, see “Employee Retirement Income Security Act” in the prospectus supplement.

### **SUPPLEMENTAL PLAN OF DISTRIBUTION**

We have agreed to sell to Barclays Capital Inc. (the “Agent”), and the Agent has agreed to purchase from us, the principal amount of the Notes covered by this pricing supplement. The Agent is committed to take and pay for all of the Notes, if any are taken.

Pricing Supplement 14Y BARC Step-up with Survivor Option Black

---



**US\$369,000**  
**BARCLAYS BANK PLC**

**STEP UP FIXED RATE NOTES DUE SEPTEMBER 16, 2024**

GLOBAL MEDIUM-TERM NOTES, SERIES A

(TO PROSPECTUS DATED AUGUST 31, 2010, AND THE  
PROSPECTUS SUPPLEMENT DATED AUGUST 31, 2010)

